PT  - JOURNAL ARTICLE
AU  - Shanthikumar, Shivanthan
AU  - Ranganathan, Sarath
AU  - Neeland, Melanie R.
TI  - Ivacaftor, not ivacaftor/lumacaftor, is associated with lower pulmonary inflammation in preschool cystic fibrosis
AID  - 10.1101/2022.03.28.22273066
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.28.22273066
4099  - http://medrxiv.org/content/early/2022/03/30/2022.03.28.22273066.short
4100  - http://medrxiv.org/content/early/2022/03/30/2022.03.28.22273066.full
AB  - Airway inflammation is a key driver of cystic fibrosis (CF) lung disease. The advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulators has the potential to transform the care of CF, however the direct effect of these therapies on lung inflammation is unknown. Here, we profile airway inflammation in bronchoalveolar lavage (BAL) of preschool aged children with CF on CFTR modulator therapy (ivacaftor or ivacaftor/lumacaftor), untreated children with CF, and age-matched healthy controls. We show that children treated with ivacaftor have lower pulmonary concentrations of inflammatory mediators CCL3, CXCL9, CCL2, IL-8, IL-1β, and IL-6 relative to untreated children with CF. Conversely, there was no significant effect of lumacaftor/ivacaftor treatment on airway inflammation. This is the first work to illustrate a difference in early life airway inflammation with CFTR treatment, highlights the effectiveness of ivacaftor in early life, and suggests that BAL inflammatory profile may represent a biomarker of therapeutic response to treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAREST CF is supported by several funding bodies, including the National Health and Medical Research Council and Cystic Fibrosis Australia. SS is supported by a Vertex Mentored Research Innovation Award. MRN is supported by funding from the Chan Zuckerberg Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval to conduct this study was obtained from the Royal Childrens Hospital Research Ethics Committee. Written and informed consent was obtained from parents or legal guardians of participants in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors